This article is more than 5 years old. Information may no longer be current.
Immune Pharmaceuticals reports 2015 financial year results and recent business highlights
Click Here to Manage Email Alerts
Immune Pharmaceuticals Inc. announced its 2015 fourth quarter and full year financial results and filed its annual report form 10-K for the fiscal year, according to a press release.
Immune reported an $8.2 million, or $0.27 per share, loss for the quarter ending Dec. 31, 2015 compared with a $7 million loss for the quarter ending Dec. 31, 2014. The company provided a net year loss of $24.1 million in 2015 compared with a $24.4 million loss for the year ending Dec. 31, 2014.
The company established a new leadership team in New York City at the Alexandria Center for Life Sciences, enrolled patients into a Phase 2 clinical trial for bertilimumab in ulcerative colitis, acquired worldwide rights to NanoCyclo and received FDA clearance for its investigational new drug application for bertilimumab, allowing for clinical trial expansion in the U.S., according to the release.
“We expect 2016 to be an important year for Immune, with several anticipated data milestones for the company’s product candidates, while we seek to unlock the potential value of our pipeline through financing and strategic partnering opportunities of specific asset groups,” Daniel Teper, MD, CEO of Immune Pharmaceuticals Inc., said in the release.
Reference: www.immunepharma.com